Operational Update and announcement of the initiation of B2B clinical decision support system program – May 1, 2023



nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) provides an operational update for its YMI machine learning-based mental health assessment program and announces initiation of its B2B clinical decision support system (“CDSS”) program.


Calgary, Alberta – May 1, 2023

For Immediate Release – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTCQB:NDATF) provides an operational update for its YMI machine learning-based mental health assessment program and announces initiation of its clinical decision support system (“CDSS”) program. The Corporation reports that its YMI predictive mental health assessment program is fully functional and is being marketed direct-to-consumers (“B2C”) in New York State and California State. Preliminary statistics are expected at the end of May, 2023 which will help provide direction for B2C marketing and advertising channels. A YMI Free Trial is available to all at ymihealth.ca

The Corporation further announces that it has initiated the search for a qualified third-party institution to conduct a clinical trial in preparation for launch of the clinical decision support system (“CDSS”) aspect of the YMI application. The YMI CDSS is designed for primary physicians, including those in Family Medicine and General Practice, who are not fully trained in mental health diagnosis and treatment, but are often the first point of contact with the mental health system for patients with mental health concerns. According to the AAMC* there are approximately 120,000 of these primary physicians in the United States. As part of the CDSS program, the Corporation will explore strategic relationships with electronic medical records (“EMR”) and electronic health records (“EHR”) companies that are seeking to add a mental health aspect to their software offerings. EMR and EHR software platforms are used to manage digital patient “charts” and are widely used by primary physicians.



About YMI

YMI uses a holistic, evidence-based, objective data from whole life experiences to predict why you are who you are, and applies this knowledge towards a fuller understanding of how to improve your mental wellbeing. After registering at ymihealth.ca users are given access to a private, in-depth survey that applies artificial intelligence using a person’s genetic expressions, childhood environment, habits, phobias, lived experiences and lifestyle. Upon completion of the survey, YMI generates a personalized graphic report predicting a person’s predisposition for seven mental conditions including anxiety, depression, post-traumatic stress disorder, obsessive compulsive disorder, alcoholism, and personality disorders both current and forward in time. The downloadable report may be used for reference as the user considers changes to their lifestyle that may help improve their mental wellbeing and mental health journey. The service also helps connect users with therapists who are prepared to help with next steps, providing further clarity and treatment as required.


About nDatalyze Corp.:

nDatalyze Corp. generates technology-based, health-related solutions. It’s machine-learning processed, online consumer mental health application known as “YMI” is based on the Corporation’s proprietary Reference Database consisting of >1200 biometric records complete with associated electroencephalogram (“EEG”) data. YMI has only recently begun its initial staged launch and accordingly the Corporation cannot accurately predict if or when this application will become a profit generator.



nDatalyze Corp.
James Durward, President and CEO
Telephone: (403) 689-3901
Email: [email protected]

Website: www.ndatalyze.com


Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.